

Private and confidential

24 November 2025

The Board of Directors
Charmacy Pharmaceutical Co., Ltd.
No. 235, Song Shan North Road
Longhu District
Shantou City
Guangdong Province
PRC

Dear Sirs,


**Re: Charmacy Pharmaceutical Co., Ltd. (the “Company”)
Renewal of continuing connected transactions in relation to framework loan agreement (the
“Subject Matter”)**

We refer to the circular of the Company dated 24 November 2025 (the “**Circular**”) in relation to, among other things, the Subject Matter. Unless otherwise specified, capitalised terms used in this letter shall have the same meaning as ascribed to them in the Circular.

We hereby give, and we confirm that we have not withdrawn, our written consent to the issue of the Circular with the inclusion of our letter of advice dated 24 November 2025 and/or references to our name in the form and context in which they respectively appear.

We hereby consent to this letter being made available for inspection as described in the appendix to the Circular.

Yours faithfully,
For and on behalf of
Kingsway Capital Limited



Stanley Chung
Managing Director